Nanobiotherapeutic Based Blood Substitutes
Regular price
€285.20
14 days return policy
Shipping & Delivery
A
Age Group_Uncategorized
Age Group_Uncategorized
Albumin-derived Perfluorocarbon
and Anemia
Antioxidant
Ascorbic Acid
automatic-update
B01=Chengmin Yang
B01=Hiromi Sakai
B01=Johnathan S Jahr
B01=Leif Bulow
B01=Thomas Ming Swi Chang
Biodegradable
Blood Brain Barrier Disruption and Brain Edema
Blood Substitutes
Carbon Dioxide Transport
Catalase and Carbonic Anhydrase
Category1=Non-Fiction
Category=PDT
Category=PSB
Clinical Use in South Africa
CO Therapeutics
COP=Singapore
Cysteine Mutations in Recombinant Fetal Hemoglobin
Delivery_Delivery within 10-20 working days
Dimeric ?? Subunit Exchange
Dimeric AZA+-AZA2 Subunit Exchange
Dimeric αβ Subunit Exchange
eq_bestseller
eq_isMigrated=2
eq_nobargain
eq_non-fiction
eq_science
Extraction of Superoxide Dismutase
Fluid Management
Hemoglobin Vesicles
Hemoglobin-Glutamer 250 (Bovine) [HBOC-201
Immune Function
Immune Safety Evaluation
Influence Oxidative Side-Reactions
Inhaled Nitric Oxide
Kidney
Language_English
Liver
Liver Allograft Preservation
Long Term Safety and Immunological Effects
Lumbricus Terrestris Erythrocruorin (LtEc)
Lyophilization
Mesenchymal Stem Cells
Modulation of Oxygen Affinity
Myocardial Infarction
Nano-artificial Red Blood Cells
Nanobiotherapeutic
Nanobiotherapeutic in Cell
Nanoencapsulation
O2CO Therapeutics
OAcA
Oxidative Toxicity
Oxygen Carriers
O₂/CO Therapeutics
PA=Available
Platelet Substitutes
Polyethyleneglycol-Polylactide
Polyhemoglo Polyhemoglobin-Catalase-Superoxide Dismutase
Polyhemoglobin-Catalase-Superoxide Dismutase-Carbonic Anhydrase
Polyhemoglobin-fibrinogen
Polymerized Porcine Hemoglobin
Prevention of Methemoglobin
Price_€100 and above
PS=Active
Rat Model of Hemorrhagic Shock with Transient Global Brain Ischemia
Red Blood Cell Storage
Resuscitation Strategy
Ring-Opening Polymerization
softlaunch
Spleen
Temperature Storage Stability and Pasteurization
Tissue and Organ Preservation
Transfusion Perspective
Volume Expansion
Product details
- ISBN 9789811228681
- Publication Date: 13 Jan 2022
- Publisher: World Scientific Publishing Co Pte Ltd
- Publication City/Country: SG
- Product Form: Hardback
- Language: English
Secure
checkout
Fast Shipping
Easy returns
This definitive volume will provide the reader with up to date information and the most recent science of the fast-evolving area of nanobiotherapeutic-based blood substitutes. Long studied, there are recent updates that make their use in patients more promising, and with one product approved for human use, many more in the pipeline. These include 2nd generations and even third generation ones, the later with enhancement of red blood cell functions. In addition, there are carefully written and referenced updates on the recent history and products in the field, complete with pathophysiologic and pharmacologic studies to validate and verify the efficacy and safety of many of these new products.
Thomas Ming Swi Chang, OC, MD, CM, PhD, FRCPC, FRS[C], Director, Artificial Cells & Organs Research Centre, Professor Emeritus of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Director, " Chang Artificial Cell Translation Research Institute" Faculty of Medicine, Shenzhen University, China; Director, "Academician TMS Chang Research station" Shantou University Medical School, China; Honorary Professors at Peking Union Medical College; Blood Transfusion Institute of the Chinese Academy Medical Sciences and Nankai University; Honorary President, International Society of Artificial Cells, Blood Substitutes & Biotechnology. Editor in Chief, Artificial Cells, Nanomedicine & Biotechnology, an international Journal, Editor in Chief, Regenerative Medicine, Artificial Cells & Nanomedicine, Book Series.
He invented the first artificial red blood cell during his BSc at McGill in 1957. There was no initial interest. He persisted while studying for his MD then PhD (Chang Science 1964, Nature 1971). By breaking "out of the box" of reproducing biological cells, he prepares artificial cells with (1) DIMENSIONS: from macro, micro, nano to soluble nanobiotechnological complexes. (2) CONTENTS; biological cell contents, cells, stem cells, vaccines, magnetic material, adsorbents, (3) MEMBRANES: biological and polymeric with variations in permeability, biodegradability, biocompatibility, targeting abilities etc. His 2019 review https://www.tandfonline.com/doi/full/10.1080/21691401.2019.1577885 shows that ARTIFICIAL CELL has evolved into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent hemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology.
Jonathan S Jahr, MD, DABA, FASA, is Professor Emeritus of Anesthesiology and Perioperative Medicine at UCLA. He has distinguished himself by authoring or co-authoring over 200 publications, co-editing a textbook, and serving on multiple editorial boards of major journals and as a reviewer for the NIH and FDA. His leadership in oxygen therapeutics, from managing and publishing major clinical trials, to understanding the impact of hemoglobin based oxygen carriers on coagulation, have created value for the entire scientific community, and helped foster future products to be developed and tested. As lead investigator in the Hemopure trial in elective orthopedic patients, he presented the largest non-trauma database of subjects receiving an HBOC, and combined with the studies of Hemopure, PolyHeme, and Hemosol, allowed for post-marketing study of Hemopure in South Africa. His animal studies with Oxyglobin in hemodynamics, oxygen delivery, intravital microscopy, laboratory interference, coagulation added to the knowledge base for this FDA and EU approved veterinary product for canine anemia. Additionally, his contributions to major acute pain and other anesthetic medications have bettered patient's care and lives.
Hiromi Sakai received PhD (DEng) in polymer chemistry in 1994 from Waseda Univ., Tokyo, with a thesis entitled "Hemoglobin-vesicles (HbV) as a molecular assembly" (Supervisor, late Prof. E Tsuchida), and since then he has continuously studied the production, safety and efficacy evaluations of HbV. In 1996-1998 he studied at Dept. Bioengineering, UC San Diego (Supervisor, Prof. M Intaglietta) and evaluated the microvascular responses to HbV injection. After coming back to Tokyo, he studied improvement of the stabilization and biocompatibility of HbV and evaluated its safety and efficacy by animal experiments. In 2006 he received PhD (DMedSci) from Keio Univ. School of Medicine (Supervisor, Prof. K Kobayashi). Dr Sakai was a Lecturer and an Associate Professor at Research Institute for Sci.&Eng. Waseda Univ. in 1998-2009, and PI at Waseda Bioscience Research Institute in Singapore in 2009-2013. From 2013 he has been the Professor of Chemistry, Nara Medical University, Kashihara, Japan. He is the chief investigator of the artificial red cells project, aiming at clinical applications, which has been supported by Ministry of Health Labour and Welfare, Japan (MHLW) and the Japan Agency for Medical Research and Development (AMED). From 2019 he is the fourth president of the Society of blood Substitutes, Japan (SBSJ).
